Companies: 10,795·Total market cap: $144.5T
Ascendis Pharma A/S

Ascendis Pharma A/S

ASNDNASDAQHealthcare● Active
$204.25
$-6.20(-2.95%)
Market Cap$12.6B
P/E Ratio
52W High$250.74
52W Low$160.86
Overview

Ascendis Pharma A/S (ASND) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

asnd · stock forecast · 25 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 25 Wall Street analysts in the past 3 months

SellBuy

Buy

25 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
23
Hold
2
Sell
0
Strong Sell
0
Total: 25 · Buy rate: 92.0%

12-Month Price Target

High

$345

Consensus

$288

+40.0% upside

Low

$250

Median: $267.5 · Last Close: $205.32

The Ascendis Pharma A/S (ASND) analyst consensus is Buy, based on ratings from 25 Wall Street analysts over the past 3 months. The average 12-month ASND price target is $287.50, representing +40.0% upside from the current price of $205.32.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $288 (40.0%)

Consensus Target

$287.50

40.0% upside

High Target

$345

68.0%

Low Target

$250

21.8%

Current Price

$205.32

as of today

Based on analyst price targets, the ASND stock price prediction for the next 12 months ranges from $250 to $345. The consensus ASND price forecast of $287.50 implies 40.0% upside from the current price of $205.32.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$195.055.00%

1-day model range: $194.13–$195.98. Peak: $195.98 (-5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$249+21.3%
2028$284+38.2%
2029$309+50.6%
2030$327+59.5%
2031+65.6%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

7%0%93%
1Buy
0Neutral
13Sell
RSI (14)23.5Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · ASND · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$213.60SELL
MA 10$222.33SELL
MA 20$232.04SELL
MA 50$232.32SELL
MA 100$229.42SELL
MA 200$216.74SELL
Current $ASND · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$213.47SELL
EMA 10$220.15SELL
EMA 20$226.49SELL
EMA 50$229.83SELL
EMA 100$226.50SELL
EMA 200$214.66SELL
Current $ASND · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Evercore ISI Group2026-05-15
Maintains
OutperformOutperform
Barclays2026-05-11
Maintains
OverweightOverweight
Wells Fargo2026-05-08
Maintains
OverweightOverweight
B of A Securities2026-04-16
Maintains
BuyBuy
Wedbush2026-04-09
Maintains
OutperformOutperform
RBC Capital2026-03-03
Maintains
OutperformOutperform
Oppenheimer2026-02-12
Maintains
OutperformOutperform
Wedbush2026-02-12
Maintains
OutperformOutperform
B of A Securities2026-01-30
Maintains
BuyBuy
Wells Fargo2026-01-20
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on Ascendis Pharma A/S (ASND) stock. Of the recent 214 rating actions, 6 were upgrades and 6 were downgrades. 25 analysts currently cover ASND.

Analyst Recommendation Trends

Buy ratings13↑ +2
Hold ratings00
Sell ratings00

ASND analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 3 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$1.3B

↓ 45.1% YoY

Revenue Next Year

$1.9B

↑ 44.4% YoY

EPS This Year

$13.52

EPS Next Year

$9.47

↓ 30.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ASND EPS of $13.52 for the current fiscal year, based on estimates from 10 analysts. The ASND revenue forecast is $1.3B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ASND stock forecast is supported by two independent data sources: analyst consensus ratings from 25 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ASND price target is $287.50 (+40.0% upside), with an analyst consensus of Buy.

The ASND short-term stock prediction for tomorrow is $195.05 (-5.00%). The ASND stock price prediction for 2027 estimates an average of $249. The ASND stock prediction for 2030 projects a range of $310–$344.

Ascendis Pharma A/S trades on NASDAQ under the ticker ASND. The ASND stock outlook for 2027 is broadly positive, supported by a Buy consensus among 92% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ASND forecast · 8 questions

According to 25 Wall Street analysts, the average 12-month ASND price target is $287.50, with a high forecast of $345.00 and a low of $250.00. The median price target is shown in the chart above when available. This implies +40.0% potential upside from the current price of $205.32.

ASND price targetWhat is ASND price targetASND analyst price targetASND 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.